Details for New Drug Application (NDA): 208552
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
Summary for 208552
Tradename: | RHOFADE |
Applicant: | Epi Hlth |
Ingredient: | oxymetazoline hydrochloride |
Patents: | 8 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 208552
Physiological Effect | Increased Sympathetic Activity Vasoconstriction |
Medical Subject Heading (MeSH) Categories for 208552
Suppliers and Packaging for NDA: 208552
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552 | NDA | Allergan, Inc. | 0023-5300 | 0023-5300-30 | 1 TUBE in 1 CARTON (0023-5300-30) / 30 g in 1 TUBE |
RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552 | NDA | Allergan, Inc. | 0023-5300 | 0023-5300-35 | 1 BOTTLE, PUMP in 1 CARTON (0023-5300-35) / 30 g in 1 BOTTLE, PUMP |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CREAM;TOPICAL | Strength | 1% | ||||
Approval Date: | Jan 18, 2017 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jun 11, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jun 11, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jun 11, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS |
Complete Access Available with Subscription